Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer.

VIENNA, Austria, October 31 /PRNewswire/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today the presentation of updated results from its Phase 3 clinical trial of the investigational radiation sensitizer EFAPROXYN(TM) (efaproxiral) in patients with brain metastases. Preliminary data from the Phase 3 study, called REACH, were first announced in April 2003.

John H. Suh, M.D., Director, Gamma Knife Center, Clinical Director, Radiation Oncology, Brain Tumor Institute at the Cleveland Clinic Foundation and the study's lead investigator presented the findings in an oral ...

Read the rest of this article with a Free Trial at HighBeam Research.